Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae infections

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 7, 2017, Pages

  King, Madeline ^a   Heil, Emily ^b   Kuriakose, Safia ^c,k   Bias, Tiffany ^d   Huang, Vanthida ^e   El Beyrouty, Claudine ^f   McCoy, Dorothy ^c,g   Hiles, Jon ^h   Richards, Lynette ^c   Gardner, Julianne ⁱ   Harrington, Nicole ⁱ   Biason, Kenneth ^c   Gallagher, Jason C ^j  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c ST JOSEPH S REGIONAL MEDICAL CENTER   (United States)

^d HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^e HonorHealth John C Lincoln Medical Center   (United States)

^f THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^g HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^h IU   (United States)

ⁱ CHRISTIANA HOSPITAL   (United States)

^j TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^k FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

more..

Author keywords

Antibiotic resistance; Beta lactamases; Carbapenemase

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; CARBAPENEM RESISTANT ENTEROBACTERIACEAE INFECTION; CHARLSON COMORBIDITY INDEX; ENTEROBACTERIACEAE INFECTION; HOSPITAL MORTALITY; HUMAN; KLEBSIELLA PNEUMONIAE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PITT BACTEREMIA SCORE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; UNITED STATES; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CLINICAL TRIAL; DRUG EFFECTS; ENTEROBACTERIACEAE; MICROBIAL SENSITIVITY TEST; MULTICENTER STUDY; MULTIDRUG RESISTANCE; PATHOGENICITY;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASE INHIBITORS; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CARBAPENEMS; CEFTAZIDIME; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HOSPITAL MORTALITY; HUMANS; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES;

EID: 85021996891     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00449-17     Document Type: Article

References (12)

1. van Duin D, Kaye KS, Neuner EA, Bonomo RA. 2013. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis 75:115–120. https://doi.org/10.1016/j.diagmicrobio.2012.11.009.
2. Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. 2014. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis 20:1170–1175. https://doi.org/10.3201/eid2007.121004.
3. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y. 2012. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 56: 2108–2113. https://doi.org/10.1128/AAC.06268-11.
4. Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. 2013. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial. J Antimicrob Chemother 68:1183–1192. https://doi.org/10.1093/jac/dks523.
5. Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, Llorens L, Newell P, Pachl J. 2016. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis 62:1380–1389. https://doi.org/10.1093/cid/ciw133.
6. Lagacé-Wiens P, Walkty A, Karlowsky JA. 2014. Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core Evid 9:13–25. https://doi.org/10.2147/CE.S40698.
7. CDC. 2017. Centers for Disease Control and Prevention/National Healthcare Safety Network Surveillance definitions for specific types of infections. https://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf. Accessed 10 December 2016.
8. Charlson ME, Pompei P, Ales KL, MacKenzie CR. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383. https://doi.org/10.1016/0021-9681(87)90171-8.
9. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, Mulazimoglu L, Trenholme G, Klugman KP, Bonomo RA, Rice LB, Wagener MM, McCormack JG, Yu VL. 2004. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med 140:26–32. https://doi.org/10.7326/0003-4819-140-1-200401060-00008.
10. Gotts JE, Matthay MA. 2016. Sepsis: pathophysiology and clinical management. BMJ 353:i1585. https://doi.org/10.1136/bmj.i1585.
11. CLSI. 2015. Performance standards for antimicrobial susceptibility testing; 18th informational supplement M100. CLSI, Wayne, PA.
12. Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, Press EG, Kreiswirth BN, Clancy CJ, Nguyen MH. 2016. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 63: 1615–1618. https://doi.org/10.1093/cid/ciw636.